Tissue expression of CA 125 in benign and malignant lesions of ovary and fallopian tube: A comparison with CA 19-9 and CEA
- 1 March 1989
- journal article
- research article
- Published by Elsevier in Gynecologic Oncology
- Vol. 32 (3) , 297-302
- https://doi.org/10.1016/0090-8258(89)90628-8
Abstract
No abstract availableThis publication has 19 references indexed in Scilit:
- The CA 125 assay as a predictor of clinical recurrence in epithelial ovarian cancerAmerican Journal of Obstetrics and Gynecology, 1986
- Ovarian cancer antigen CA 125 levels in pelvic inflammatory disease and pregnancyCancer, 1986
- Simultaneous inhibition of endogenous avidin-binding activity and peroxidase applicable for the avidin-biotin system using monoclonal antibodiesHistochemistry and Cell Biology, 1985
- Monitoring human ovarian carcinoma with a combination of CA 125, CA 19-9, and carcinoembryonic antigenAmerican Journal of Obstetrics and Gynecology, 1984
- Initial clinical evaluation of an immunoradiometric assay for CA 19‐9 using the nci serum bankInternational Journal of Cancer, 1984
- Reactivity of a monoclonal antibody with human ovarian carcinoma.Journal of Clinical Investigation, 1981
- Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures.Journal of Histochemistry & Cytochemistry, 1981
- Colorectal carcinoma antigens detected by hybridoma antibodiesSomatic Cell and Molecular Genetics, 1979
- Continuous cultures of fused cells secreting antibody of predefined specificityNature, 1975
- SPECIFIC CARCINOEMBRYONIC ANTIGENS OF THE HUMAN DIGESTIVE SYSTEMThe Journal of Experimental Medicine, 1965